The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy
Cancers · 29.08.2024 · 16 (17) · 3016
DOI: 10.3390/cancers16173016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.08.2024. Verfasst von Emma Melia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Medical Research Council, NIH HHS.
Abstract (Originalsprache)
Radiotherapy is one of the main cancer treatments being used for ~50% of all cancer patients. Conventional radiotherapy typically utilises X-rays (photons); however, there is increasing use of particle beam therapy (PBT), such as protons and carbon ions. This is because PBT elicits significant benefits through more precise dose delivery to the cancer than X-rays, but also due to the increases in linear energy transfer (LET) that lead to more enhanced biological effectiveness. Despite the radiotherapy type, the introduction of DNA damage ultimately drives the therapeutic response through stimulating cancer cell death. To combat this, cells harbour cell cycle checkpoints that enables time for efficient DNA damage repair. Interestingly, cancer cells frequently have mutations in key genes such as TP53 and ATM that drive the G1/S checkpoint, whereas the G2/M checkpoint driven through ATR, Chk1 and Wee1 remains intact. Therefore, targeting the G2/M checkpoint through specific inhibitors is considered an important strategy for enhancing the efficacy of radiotherapy. In this review, we focus on inhibitors of Chk1 and Wee1 kinases and present the current biological evidence supporting their utility as radiosensitisers with different radiotherapy modalities, as well as clinical trials that have and are investigating their potential for cancer patient benefit.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
- School of Physics and Astronomy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
ORCID-Profile: Emma Melia, Jason L Parsons
Förderung
- NCI NIH HHS
- Medical Research Council
- NIH HHS
- National Institutes of Health
Zitieren
APA
Melia, E., & Parsons, J. L. (2024). The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy. Cancers, 16(17), 3016. https://doi.org/10.3390/cancers16173016
Vancouver
Melia E, Parsons JL. The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy. Cancers. 2024;16(17):3016. doi:10.3390/cancers16173016
BibTeX
@article{Melia2024,
author = {Melia, Emma and Parsons, Jason L},
title = {The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy},
journal = {Cancers},
year = {2024},
volume = {16},
number = {17},
pages = {3016},
doi = {10.3390/cancers16173016}
}
EUVIMED